BofA raises MiniMed stock price target to $28 on FDA submission

BofA Securities has increased its price target for MiniMed Group (NASDAQ:MMED) shares to $28, up from $24. Analysts maintain a Buy rating on the stock, which is currently trading at $22.42, close to its 52-week high of $22.74. The consensus among analysts is a strong buy, indicated by a rating of 1.46. MiniMed's first-quarter results showed revenue 2% above consensus estimates, with U.S. revenue growing in the high single digits and international revenue increasing on an organic basis after adjusting for an extra selling week.

The company reported 14% revenue growth over the past year, and analysts predict profitability for the year despite current losses. MiniMed submitted its Fit product to the FDA, with an expected Summer 2027 launch, and announced the Flex product's CE Mark ahead of schedule, set for November launch. BofA raised its target to $28, representing 2.0 times enterprise value to estimated 2027 sales, from $24.

The firm updated its model for first-quarter results and guidance. MiniMed Group reported $843 million in first-quarter revenue, with 15.8% organic growth year-over-year, surpassing estimates from Wells Fargo and the consensus. The growth was seen in both U.S. ($240 million) and international ($603 million) markets, with an extra selling week contributing a 4% to 6% benefit.

Other firms, including BTIG, have also raised their price targets to $28, citing progress in MiniMed's product pipeline and maintaining Buy ratings.